Mitochondrial DNA haplogroups and age-related maculopathy

Archives of Ophthalmology

Volumn 125, Issue 9, 2007, Pages 1235-1240

  Jones, Michael M ^a   Manwaring, Neil ^a   Wang, Jie Jin ^b   Rochtchina, Elena ^b   Mitchell, Paul ^b   Sue, Carolyn M ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA;

ADULT; AGED; ARTICLE; DRUSEN; FEMALE; GENETIC MARKER; GENETIC RISK; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR;

AGED; AGED, 80 AND OVER; COMPLEMENT FACTOR H; DNA, MITOCHONDRIAL; FEMALE; GENE FREQUENCY; GENETIC MARKERS; HAPLOTYPES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; MITOCHONDRIA; NEW SOUTH WALES; PREVALENCE; RISK FACTORS;

EID: 34548612004     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.9.1235     Document Type: Article

References (47)

1. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325(20):1412-1417.
2. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995;36(1):182-191.
3. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol. 1998;116(5):653-658.
4. Munoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000;118(6):819-825.
5. Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol. 2000;118(2):264-269.
6. Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2000;28(4):268-273.
7. Yates JR, Moore AT. Genetic susceptibility to age related macular degeneration. J Med Genet. 2000;37(2):83-87.
8. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108(4):697-704.
9. Sepp T, Khan J, Thurlby D, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci. 2006;47(2):536-540.
10. Souied E, Leveziel N, Richard F, et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis. 2005;11:1135-1140.
11. Hageman G, Anderson D, Johnson L, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102(20):7227-7232.
12. Seddon JM, Gensler G, Klein ML, Milton RC. C-reactive protein and homocysteine are associated with dietary and behavioral risk factors for age-related macular degeneration. Nutrition. 2006;22(4):441-443.
13. Dasch B, Fuhs A, Behrens T, et al. Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. Arch Ophthalmol. 2005;123(11):1501-1506.
14. Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology. 2005;112(12):2076-2080.
15. McGwin G, Hall TA, Xie A, Owsley C. The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br J Ophthalmol. 2005;89(9):1166-1170.
16. Schaumberg D, Christen W, Kozlowski P, Miller D, Ridker P, Zee RY. A prospective assessment of the Y402H variant in complement factor H, genetic variants in C-reactive protein, and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2006;47(6):2336-2340.
17. Baudouin SV, Saunders D, Tiangyou W, et al. Mitochondrial DNA and survival after sepsis: a prospective study. Lancet. 2005;366(9503):2118- 2121.
18. Harman D. The aging process. Proc Natl Acad Sci U S A. 1981;78(11):7124-7128.
19. Biousse V, Newman NJ. Neuro-ophthalmology of mitochondrial diseases. Semin Neurol. 2001;21(3):275-291.
20. Sue C, Mitchell P, Crimmins D, Moshegov C, Byrne E, Morris J. Pigmentary retinopathy associated with the mitochondrial DNA 3243 point mutation. Neurology. 1997;49(4):1013-1017.
21. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia: the Blue Mountains Eye Study. Ophthalmology. 1996;103(3):357-364.
22. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology. 1995;102(10):1450-1460.
23. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study [erratum appears in Ophthalmology. 2002;109(9):1588]. Ophthalmology. 2002;109(6):1092-1097.
24. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98(7):1128-1134.
25. Bird A, Bressler N, Bressler S, et al. An international classification and grading system for age-related macular degeneration: the International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39(5):367-374.
26. Sue C, Crimmins D, Quigley A, et al. Detection of MELAS point mutation 3243 in muscle, blood and hair follicles. J Neurol Sci. 1998;161(1):36-39.
27. Torroni A, Huoponen K, Francalacci P, et al. Classification of European mtDNAs from an analysis of three European populations. Genetics. 1996;144(4):1835-1850.
28. van der Walt JM, Nicodemus KK, Martin ER, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003;72(4):804-811.
29. Autere J, Moilanen JS, Finnila S, et al. Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum Genet. 2004;115(1):29-35.
30. van der Walt JM, Dementieva YA, Martin ER, et al. Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett. 2004;365(1):28-32.
31. Majamaa K, Finnila S, Turkka J, Hassinen IE. Mitochondrial DNA haplogroup U as a risk factor for occipital stroke in migraine. Lancet. 1998;352(9126):455-456.
32. Kalman B, Li S, Chatterjee D, et al. Large scale screening of the mitochondrial DNA reveals no pathogenic mutations but a haplotype associated with multiple sclerosis in Caucasians. Acta Neurol Scand. 1999;99(1):16-25.
33. Ruiz-Pesini E, Lapena A, Diez-Sanchez C, et al. Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am J Hum Genet. 2000;67(3):682-696.
34. Sadun F, De Negri AM, Carelli V, et al. Ophthalmologic findings in a large pedigree of 11778/Haplogroup J Leber hereditary optic neuropathy [erratum appears in Am J Ophthalmol. 2004;137(4):793]. Am J Ophthalmol. 2004;137(2):271-277.
35. Brown MD, Starikovskaya E, Derbeneva O, et al. The role of mtDNA background in disease expression: a new primary LHON mutation associated with Western Eurasian haplogroup J. Hum Genet. 2002;110(2):130-138.
36. Howell N, Herrnstadt C, Shults C, Mackey DA. Low penetrance of the 14484 LHON mutation when it arises in a non-haplogroup J mtDNA background. Am J Med Genet A. 2003;119(2):147-151.
37. Tsao K, Aitken PA, Johns DR. Smoking as an aetiological factor in a pedigree with Leber's hereditary optic neuropathy. Br J Ophthalmol. 1999;83(5):577-581.
38. Sadun AA, Carelli V, Salomao SR, et al. Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy. Am J Ophthalmol. 2003;136(2):231-238.
39. Anderson S, Bankier A, Barrell B, et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290(5806):457-465.
40. Manwaring N, Jones M, Wang J, Rochtchina E, Mitchell P, Sue C. Prevalence of mtDNA haplogroups in an Australian population. Intern Med J. 2006;36(8):530-533.
41. Cruickshanks KJ, Wiley TL, Tweed TS, et al. Prevalence of hearing loss in older adults in Beaver Dam, Wisconsin: the Epidemiology of Hearing Loss Study. Am J Epidemiol. 1998;148(9):879-886.
42. Gates GA, Cooper JC Jr, Kannel WB, Miller NJ. Hearing in the elderly: the Framingham cohort, 1983-1985, part I: basic audiometric test results. Ear Hear. 1990;11(4):247-256.
43. Herrnstadt C, Elson J, Fahy E, et al. Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am J Hum Genet. 2002;70(5):1152-1171.
44. Torroni A, Lott MT, Cabell MF, Chen YS, Lavergne L, Wallace DC. mtDNA and the origin of Caucasians: identification of ancient Caucasian-specific haplogroups, one of which is prone to a recurrent somatic duplication in the D-loop region. Am J Hum Genet. 1994;55(4):760-776.
45. Liang F, Godley B. Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration. Exp Eye Res. 2003;76(4):397-403.
46. Liles MR, Newsome DA, Oliver PD. Antioxidant enzymes in the aging human retinal pigment epithelium. Arch Ophthalmol. 1991;109(9):1285-1288.
47. Tate DJ Jr, Newsome DA, Oliver PD. Metallothionein shows an age-related decrease in human macular retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1993;34(7):2348-2351.